Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data? - Wikidata - awgldk - TriplyDB

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?

http://www.wikidata.org/entity/Q34183220

about

A Prospective Evaluation of the Effects of Prevalent Depressive Symptoms on Disease Activity in Rheumatoid Arthritis Patients Treated With Biologic Response Modifiers.Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.Abatacept: a review of its use in the management of rheumatoid arthritis.

P2860

Q37100388-EF32D437-D516-4417-9A3D-9ED343127FD6 Q37465523-FD9DEB7D-EAEB-45F2-AC4C-6A07357FE622 Q38116472-DA92D90D-9C4D-4994-8C5E-374365984F5F

P2860

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?

http://www.wikidata.org/entity/Q34183220

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?

@ast

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?

@en

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?

@nl

type

label

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?

@ast

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?

@en

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?

@nl

prefLabel

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?

@ast

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?

@en

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?

@nl

P1433

Q34183220-BB269052-0103-48A5-955E-0776F8887BE9

P1476

Q34183220-626B9B7D-2E83-42F0-B661-AA2F8D2C12B9

P2093

Q34183220-3931DBC1-1167-48B0-94F2-A2748990C236

P2860

Q34183220-40BD7756-9106-405F-82D1-EEF1B3341E2C

Q34183220-41E0C614-1A65-46CD-A659-E64C3681014A

Q34183220-51CAB895-6520-40E2-B939-0EDB1D6841C4

Q34183220-5C953324-5AAF-4FE6-987A-69ACF2138BCE

Q34183220-6ABAEADC-3E9F-4937-9976-CA37D6CF1DBC

Q34183220-6DBDC3A9-8448-4258-B202-E28B09DCCBE7

Q34183220-7B19FD6A-D05C-430D-A843-75F83CE8D7F8

Q34183220-8432484D-E78C-4D68-BE21-58A6C25D742B

Q34183220-8A02BC4E-5270-4AE3-8E57-DFB8F0F6A185

Q34183220-8DDABF7E-964D-4F16-A277-781BE85FAF19

P2888

Q34183220-89C2D6EE-1463-4871-882C-DFF11097C30A

P304

Q34183220-4D15D4D0-B962-4633-AD8F-817ED22F16BE

P31

Q34183220-026773AF-5844-4D5F-9648-9F9BAC1B0BD2

P356

Q34183220-47703486-E013-4AA4-9F31-B5D04396F69F

P433

Q34183220-658FC97E-8053-446A-AA71-860FF03F4C31

P478

Q34183220-BEB07788-6AE9-4935-AF18-5ACDBDE4D116

P577

Q34183220-CA0BEDEC-CE12-4146-9141-47817C7E1550

P6179

Q34183220-D31A8134-C1D0-40B3-846E-90FB1A874BB0

P698

Q34183220-2B665813-3B3D-4EFA-84DE-9FEB2CC4B5CE

P356

11631320-000000000-00000

P1433

P1476

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?

@en

P2093

Marc C Levesque

http://www.w3.org/2001/XMLSchema#string

P2860

The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects.

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US.

New therapies for treatment of rheumatoid arthritis.

The use of TNF-alpha blocking agents in rheumatoid arthritis: an update.

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.

Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis.

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs.

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

P2888

11631320-000000000-00000

P304

65-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11631320-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1049317871

http://www.w3.org/2001/XMLSchema#string

P698

22385403

http://www.w3.org/2001/XMLSchema#string